Clinical Trials Logo

Filter by:
NCT ID: NCT05325229 Recruiting - Clinical trials for Platinum-resistant Recurrent Ovarian Cancer

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Start date: August 18, 2022
Phase: Phase 2
Study type: Interventional

This trial is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) combined with Bevacizumab and the pharmacokinetic characteristics of Docetaxel in patients with platinum-resistant recurrent ovarian cancer.

NCT ID: NCT05325190 Recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Granisetron Transdermal Patch System for Prevention of CINV by CapeOX

Start date: October 10, 2021
Phase: Phase 2
Study type: Interventional

This study aims to explore the prevention of delayed chemotherapy induced by CAPOX regimen with granisetron transdermal patch。

NCT ID: NCT05324774 Recruiting - Clinical trials for Diabetic Macular Edema

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Start date: February 28, 2022
Phase: Phase 3
Study type: Interventional

Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind, parallel active-controlled study.

NCT ID: NCT05324631 Recruiting - Clinical trials for Non-radiographic Axial Spondyloarthritis

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

Start date: August 16, 2022
Phase: Phase 3
Study type: Interventional

This study is to evaluate the efficacy and safety of SHR0302 in subjects with active non-radiographic axial spondyloarthritis.

NCT ID: NCT05324423 Recruiting - Gout Clinical Trials

To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout

Start date: October 18, 2021
Phase: Phase 1
Study type: Interventional

A single-center, open-access study to evaluate drug interactions between XNW3009, febuxostat, and colchicine in patients with gout

NCT ID: NCT05324384 Recruiting - Clinical trials for Hemangioendothelioma

Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

Start date: April 5, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of different doses of sirolimus in the maintenance treatment of kaposiform hemangioendothelioma.

NCT ID: NCT05324332 Recruiting - Prostate Cancer Clinical Trials

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

Start date: April 15, 2022
Phase: N/A
Study type: Interventional

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.

NCT ID: NCT05323929 Recruiting - Clinical trials for Early Gastric Cancer

The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by ESD, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.

NCT ID: NCT05323890 Recruiting - Clinical trials for Advanced Esophageal Squamous Cell Cancer

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Start date: April 20, 2022
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the safety and feasibility of neoadjuvant tislelizumab combined with chemoradiotherapy in patients with resectable esophageal squamous cell cancer. The tumor microenvironment and circulating immunological biomarkers in these patients were further evaluated to explore the factors affecting the efficacy of neoadjuvant therapy for esophageal cancer. This study will provide valuable information for further prospective clinical trials of neoadjuvant anti-PD-1 and other immunotherapy in esophageal cancer patients.

NCT ID: NCT05323227 Recruiting - Clinical trials for Coronary Artery Disease

Lp(a) With CCTA Assessed Parameters and Clinical Outcomes

CHART-ACCORD
Start date: March 20, 2016
Phase:
Study type: Observational

Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed tomography angiography (CCTA) as well as their prognostic value.